Who Paid My Doc
Scott Hacker
La Mesa, CA Medical Doctor
NPI 1750450805 CMS profile 1292923
5565 Grossmont Center Dr, Bldg 3 Suite 256, La Mesa, CA 91942
General payments
$434,028
Research payments
$497,410
Ownership & investment interest
$0
Research they led as principal investigator
$2,560,899
Through program year 2025, Scott Hacker of La Mesa, CA is reported in the CMS Open Payments database as having received $434,028 across 170 general payments and $497,410 in research payments paid to them. Separately, studies naming them as principal investigator received $2,560,899 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,389 | 12 | |
| 2025 | Research | $10,391 | 4 | |
| 2024 | General | $513 | 8 | |
| 2024 | Research | $222,622 | 13 | |
| 2023 | General | $9,222 | 11 | |
| 2023 | Research | $264,397 | 18 | |
| 2022 | General | $31,956 | 27 | |
| 2021 | General | $124,659 | 61 | |
| 2020 | General | $137,392 | 24 | |
| 2019 | General | $125,897 | 27 |
Beside peers
- Scott Hacker
- California median
- Middle half of California
- National median
In program year 2025, general payments to Scott Hacker were reported at $4,389. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Scott Hacker | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $125,897 | $161 | $50–$652 | $163 |
| 2020 | $137,392 | $114 | $34–$392 | $114 |
| 2021 | $124,659 | $137 | $41–$509 | $132 |
| 2022 | $31,956 | $152 | $48–$573 | $149 |
| 2023 | $9,222 | $162 | $50–$581 | $160 |
| 2024 | $513 | $162 | $52–$583 | $164 |
| 2025 | $4,389 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
16
Drug cost
$274
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 16 | $274 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$335,368
Medicare patients
738
Services billed
9,685
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 71% | |
| Ischemic heart disease | 26% | |
| Diabetes | 25% | |
| Depression | 19% | |
| Chronic kidney disease | 18% | |
| Atrial fibrillation | 17% | |
| Heart failure | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 | Office | 92 | 4,879 | $28,045 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 | Office | 97 | 333 | $19,178 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 181 | 1,013 | $745 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 52 | 138 | $718 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
205 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.